Veeda Unlisted Shares
Latest unlisted share price, company overview and trading process
Quick Navigation
Company Overview
Introduction to Veeda Unlisted Share
Veeda Clinical Research Limited is among India’s prominent independent full-service Clinical Research Organizations (CROs). Founded in 2004, the company has steadily expanded its global footprint, delivering comprehensive clinical research solutions. Focused on innovation and strict regulatory adherence, Veeda supports pharmaceutical companies throughout the drug development lifecycle—from early-stage research to advanced clinical trials. With its established presence in the CRO industry, Veeda Clinical unlisted shares present an interesting opportunity for investors.
Read More
Business Divisions
Veeda operates across multiple specialized verticals within clinical research:
Bioavailability & Bioequivalence (BA/BE) Studies – Evaluates drug absorption and performance to meet regulatory requirements.
Pre-Clinical & Clinical Trials – Conducts Phase I, II, and III trials to aid drug development.
Bioanalytical Services – Provides advanced testing to assess drug safety and effectiveness.
Pharmacovigilance – Ensures ongoing drug safety monitoring and compliance with global regulations.
Medical Writing – Prepares regulatory documentation and scientific publications.
The company runs advanced research facilities in Ahmedabad, Mehsana, and Bangalore, equipped with modern technology to support efficient drug testing and development.
Financial Highlights
Veeda’s financial performance reflects a mix of expansion and pressure:
Revenue Growth – Revenue grew from ₹196 crore in 2021 to ₹409 crore in 2023, followed by a slight dip to ₹388 crore in 2024.
Profitability Pressure – Profit After Tax declined significantly from ₹63 crore in 2021 to a marginal loss of ₹0.3 crore in 2024.
EBITDA Trend – Margins dropped from 34.18% in 2021 to 13.66% in 2024, indicating rising operational expenses.
Higher Debt – Borrowings increased sharply from ₹24 crore in 2021 to ₹260 crore in 2024.
Asset Expansion – Total assets surged from ₹285 crore in 2021 to ₹2,040.2 crore in 2024, reflecting aggressive growth and investments.
Pros
Global Client Base – Serves clients across 27 countries, including major pharmaceutical players like Dr. Reddy’s Laboratories, Mankind Pharma, and Novugen Pharma.
Strategic Acquisitions – Acquisitions such as Heads (oncology-focused European CRO) and Bioneeds have strengthened capabilities and global reach.
Regulatory Track Record – Successfully completed 85 global inspections, ensuring compliance with authorities like USFDA and EMA.
Cons
Falling Profitability – Net Profit Margin declined sharply from 32.14% in 2021 to -0.08% in 2024.
Rising Costs – Employee and operational expenses increased significantly, affecting margins.
Increasing Debt – Borrowings rose substantially, indicating higher financial risk.Unlisted Share Details
| Detail | Information |
| Veeda Clinical Unlisted Shares Price | ₹ 462 Per Equity Share |
| Minimum Lot Size Shares Worth | Rs. 5000 |
| 52 Week High | ₹ 575 |
| 52 Week Low | ₹ 525 |
| PAN Number | AACCC3633Q |
| ISIN | INE01HQ01026 |
| CIN | U73100GJ2004PLC044023 |
| Depository | NSDL & CDSL |
| RTA | Link Intime |
| Fundamentals | Value |
| Market Cap | 488812.5 CR |
| P/B Ratio | 16.1 |
| ROE (%) | 38% |
| EPS | 49.24 |
| PE RATIO | 40.11 |
| DEBT TO EQUITY | 0.02 |
| BOOK VALUE | 122.64 |
| FACE VALUE | 1 |
| Total Shares | 2475000000 |
Promoters or Management
Shareholding Pattern 2025
How to Buy or Sell Veeda Clinical UNLISTED Shares
- Check the latest price mentioned above
- Click on the Chat on WhatsApp button
- Share your requirement (Buy or Sell quantity)
- Price and availability will be confirmed
- Transaction is completed offline with proper documentation
Disclaimer: Prices mentioned are indicative and subject to market availability. Unlisted shares are illiquid and involve risk. Please consult a financial advisor before investing.
frequently asked questions
Find answers to the most common unlisted shares-related queries.
What are unlisted shares?
Unlisted shares are shares of companies that are not listed on stock exchanges like NSE or BSE but are legally traded through private transactions.
Is it legal to buy or sell unlisted shares in India?
Yes. Buying and selling unlisted shares is completely legal in India when done through proper documentation and compliant transfer processes.
How do I buy unlisted shares from your platform?
You can browse available shares, connect with us through live chat, confirm the price, complete documentation, and receive shares directly in your Demat account.
How do I sell my unlisted shares?
Simply contact us via live chat, share your holding details, confirm the selling price, and we will assist you with the complete selling and transfer process.
Can NRIs buy or sell unlisted shares?
NRIs can trade unlisted shares subject to RBI and FEMA regulations. Please contact us for specific guidance.
Do I need a Demat account to trade unlisted shares?
Yes, a Demat account is mandatory for buying or selling unlisted shares, as transfers happen electronically.
How long does it take to transfer unlisted shares?
The transfer process generally takes 2–5 working days, depending on documentation and company approval timelines.
Are prices shown on the website final?
Prices are indicative and may change based on market demand. Final prices are confirmed at the time of order through live chat.
What documents are required for trading?
Basic documents include PAN, Demat details, and KYC documents as per regulatory requirements.
Is my transaction secure?
Yes. All transactions are handled securely with proper agreements, verified documentation, and compliant transfer mechanisms.